InspireMD, Inc. (NSPR) |
| 0.9608 0.061 (6.76%) 05-29 15:06 |
| Open: | 0.9 |
| High: | 0.9998 |
| Low: | 0.9 |
| Volume: | 211,015 |
| Market Cap: | 45(M) |
| PE Ratio: | -1.37 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 1.31 |
| Resistance 1: | 1.14 |
| Pivot price: | 1.05 |
| Support 1: | 0.86 |
| Support 2: | 0.72 |
| 52w High: | 2.93 |
| 52w Low: | 0.86 |
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
| EPS | -0.700 |
| Book Value | 1.270 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.065 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | -411.36 |
| Return on Assets (ttm) | -68.5 |
| Return on Equity (ttm) | -142.6 |
Fri, 22 May 2026
InspireMD (NSPR) chair Paul Stuka plans Board retirement in 2027 - Stock Titan
Thu, 21 May 2026
InspireMD (NSPR) CCO auto-sells shares to cover RSU tax obligations - Stock Titan
Fri, 15 May 2026
Velan Capital holds 4.99% of InspireMD (NASDAQ: NSPR) via 2.35M shares - Stock Titan
Fri, 15 May 2026
Director Stuka increases InspireMD (NSPR) stake with 15,000-share buys - Stock Titan
Mon, 04 May 2026
InspireMD, Inc. (NSPR) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Mon, 04 May 2026
After a recall, InspireMD says another FDA decision is due in Q3 - Stock Titan
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |